FLT Stock Recent News

TORONTO, April 30, 2025 (GLOBE NEWSWIRE) -- Volatus Aerospace Inc. (TSXV:FLT) (OTCQB:TAKOF) (Frankfurt:A3DP5Y/ABBA.F) ("Volatus" or "the Company"), a leader in aerial solutions, is pleased to announce its financial results for the twelve-month period and fourth quarter ended Dec 31, 2024 (“FY 2024” and “Q4 2024”, respectively). All dollar figures are stated in Canadian dollars, unless otherwise indicated.

Not for distribution to United States newswire services or for dissemination in the United States. TORONTO, April 28, 2025 (GLOBE NEWSWIRE) -- Volatus Aerospace Inc. (TSXV:FLT) (OTCQX:TAKOF) (Frankfurt: ABB) (“Volatus” or the “Company”) is pleased to announce that it has filed an offering document in connection with a non-brokered private placement of up to 16,666,667 units of the Company (the “Units”) at a price of $0.12 per Unit (the “Issue Price”) for gross proceeds of up to $2,000,000.04 (the “LIFE Financing”).

Actimab-A significantly potentiated and prolonged efficacy in combination with standard of care targeted therapies including hypomethylating agent azacitidine, FLT3 and menin inhibitors in in-vivo AML models Actimab-A is the only CD33 targeted radiotherapy with Actinium-225 isotope payload in development for AML and other myeloid malignancies Actimab-A is currently being advanced in several combination studies including a Phase 2/3 trial in combination with CLAG-M in relapsed/refractory AML and in combination with Venetoclax and ASTX-727, an oral hypomethylating agent from Taiho Oncology in frontline AML under a CRADA with the NCI NEW YORK , April 28, 2025 /PRNewswire/ -- Actinium Pharmaceuticals, Inc. (NYSE AMERICAN: ATNM) (Actinium or the Company), a pioneer in the development of targeted radiotherapies, today highlighted data presented at the American Association for Cancer Research (AACR) Annual Meeting supporting Actimab-A's mutation agnostic antileukemic effect and backbone the

Data presented at the American Association for Cancer Research (AACR) Annual Meeting 2025 Dose Finding completed with no dose limiting toxicities and preliminary recommended Phase 2 dose (RP2D) identified 5 of 7 best overall response evaluable patients achieved ORR (3 CR, 1 CRh and 1 morphologic leukemia-free state) across all dose cohorts, including 1 CR and 1 CRh in 3 patients in preliminary RP2D cohort 4 of 4 cCR patients were measurable residual disease (MRD) negative as assessed by local standard of care Early deep responses with SENTI-202 noted across dose levels with all cCRs ongoing as of the data cut and longest durability of 8+ months Company to host webcast to discuss the new Phase 1 SENTI-202 data today, April 28th at 8:30 AM ET; Register Here Announces certain preliminary first quarter 2025 financial results and provides pipeline update SOUTH SAN FRANCISCO, Calif., April 28, 2025 (GLOBE NEWSWIRE) -- Senti Biosciences, Inc. (Nasdaq: SNTI) (“Senti Bio” or the “Company?

TORONTO, April 15, 2025 (GLOBE NEWSWIRE) -- Volatus Aerospace Inc. (TSXV: FLT) (OTCQX: TAKOF) (Frankfurt: A3DP5Y/ABBA.F) is pleased to announce that last week it was approved by two leading North American oil and gas companies to provide drone-based aerial services in support of critical energy infrastructure. This approval follows a comprehensive flight operations review process conducted to validate Volatus' operational readiness and safety protocols.

/ NOT FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES / TORONTO, April 11, 2025 (GLOBE NEWSWIRE) -- Volatus Aerospace Inc. (TSXV: FLT) (OTCQX: TAKOF) (Frankfurt: A2JEQU) ("Volatus" or the “Company"), a leader in global aerial solutions, is pleased to announce a proposed shares-for-debt settlement aimed at enhancing shareholder value and strengthening the Company's balance sheet. Effective April 10, 2025, the Company has reached an agreement, subject to receipt of TSX Venture Exchange (“TSXV”) approval, with the holders of convertible debentures issued pursuant to a debenture indenture dated May 11, 2023 (the “Debenture Indenture”) between the Company and TSX Trust Company as trustee (the “Trustee”).

MONTREAL, March 18, 2025 (GLOBE NEWSWIRE) -- Volatus Aerospace Inc. (TSXV: FLT) (OTCQX: TAKOF) (Frankfurt: A2JEQU) ("Volatus" or "the Company") a leader in aerial solutions, invites investors, customers, and current and future stakeholders to an exclusive webinar addressing today's evolving geopolitical landscape on March 25 at 11:00 AM ET. The session will explore the challenges and opportunities arising from current global shifts, outline Volatus' strategic response, and highlight the critical role of its recent partnerships in shaping both current operations and future growth.

Advancing Aerial Intelligence with proprietary software - AIRS (Aerial Intelligence Reporting System) TORONTO, ON / ACCESS Newswire / January 30, 2025 / Volatus Aerospace Inc. (TSXV:FLT)(OTCQX:TAKOF)(Frankfurt:A2JEQU) ("Volatus" or "the Company") is pleased to announce that it has surpassed 75,000 flight hours conducting pipeline integrity monitoring. This milestone reinforces the company's leadership in aerial inspection services and underscores its commitment to supporting critical energy infrastructure with advanced monitoring solutions.

TORONTO, ON / ACCESSWIRE / January 6, 2025 / Volatus Aerospace Inc. (TSXV:FLT)(OTCQX:TAKOF)(Frankfurt:A3DP5Y) ("Volatus" or "the Company") is pleased to announce the renewal and expansion of one of its major U.S.-based power utility inspection programs for 2025. This milestone reflects the company's growing presence in the energy utilities sector and its ability to deliver innovative aerial solutions that address the evolving needs of its customers.

TORONTO, ON / ACCESSWIRE / December 30, 2024 / Volatus Aerospace Inc. (TSXV:FLT)(OTCQX:TAKOF)(Frankfurt:A3DP5Y/ABBA.F) ("Volatus" or the "Company") has, in line with TSX Venture Exchange (TSXV) guidelines and Volatus Aerospace's commitment to long-term growth, successfully converted $145,545 in preferred shares into common shares. This move, part of the original terms for the acquisition of UAViation Aerial Solutions Ltd in 2020, simplifies the Company's capital structure and enhances shareholder value.